Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by HEYDEN, S.
Right arrow Articles by FODOR, G. J
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by HEYDEN, S.
Right arrow Articles by FODOR, G. J
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1988 Oxford University Press

research-article

Coronary Heart Disease in Hypertensives: A Need to Reduce Cholesterol

SIEGFRIED HEYDEN*, KENNETH A SCHNEIDER** and GEORGE J FODOR{dagger}

* Department of Community and Family Medicine
**Department of Pathology, Duke University Medical Centre Durham, North Carolina 27710. USA.
{dagger} Department of Community Medicine, Faculty of Medicine Memorial University of Newfoundland St John's, Newfoundland, Canada

Heyden S (Department of Community and Family Medicine, Duke University Medical Centre, Durham, MC 27710, USA), Schneider K A and Fodor G J. Coronary heart disease in hypertensives: a need to reduce cholesterol. International Journal of Epidemiology 1988, 17: 784–788.

Ten international long-term hypertension intervention trials between 1980 and 1987 have resulted in significant reduction in the incidence of stroke in the treatment groups. Yet eight of these studies have shown disappointing results in the prevention of coronary heart disease (CHD).

Five hypertension intervention trials revealed high average cholesterol values at baseline. No cholesterol treatment was provided and the incidence of CHD was high. In four other trials with stratification into ‘low’ and ‘high’ baseline cholesterol levels, the incidence of CHD was considerably less in the ‘low’ cholesterol groups. Only the 10th, the Gothenburg trial, has demonstrated a marked reduction in CHD by combining antihypertensive medication with cholesterol lowering treatment Failure to reduce cholesterol in hypertensives with hypercholesterolaemia may be one explanation for the limited efficacy of antihypertensive treatment in the reduction of CHD.

We postulate that successful treatment of hypercholesterolaemla will reduce the incidence of CHD in wellcontrolled hypertensive patients to the same extent as it lowers the incidence of CHD in normotensive people.

Revised 1 May 1988


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.